Bupropion

Generic Name: Bupropion

Brand Names: Aplenzin, Auvelity, Budeprion, Contrave, Forfivo, Wellbutrin, Zyban

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈ClNO

CAS Number: 34911-55-2

Unique Ingredient Identifier: 01ZG3TPX31

Background: Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the upta...

Indication: Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation.
...

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Major Depressive Disorder (MDD), Obesity, Seasonal Affective Disorder (SAD)

Associated Therapies: Smoking, Cessation, Weight Loss

Clinical Trials

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

Phase 1

Recruiting

Conditions: Healthy Study Participants

Interventions: Drug: midazolam
Drug: metformin
Drug: bupropion
Drug: fenfluramine HCl

First Posted Date: 2024-11-07

Last Posted Date: 2024-12-13

Lead Sponsor: UCB BIOSCIENCES, Inc.

Target Recruit Count: 22

Registration Number: NCT06679413

Locations: 🇺🇸
Up0132 1001, Baltimore, Maryland, United States

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Phase 1

Active, not recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Survodutide
Drug: Bupropion
Drug: Caffeine
Drug: Midazolam

First Posted Date: 2024-08-21

Last Posted Date: 2024-12-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06564441

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

Study of Injectable Naltrexone and Oral Bupropion Among Cigarette Smokers With Schizophrenia

Phase 1

Recruiting

Conditions: Smoking Cessation

Interventions: Drug: Naltrexone (Vivitrol)
Drug: Bupropion

First Posted Date: 2024-04-18

Last Posted Date: 2024-05-16

Lead Sponsor: The University of Texas Health Science Center, Houston

Target Recruit Count: 20

Registration Number: NCT06374290

Locations: 🇺🇸
The University of Texas health Science Center at Houston, Houston, Texas, United States

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1569912
Drug: repaglinide
Drug: midazolam
Drug: bupropion

First Posted Date: 2024-04-16

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT06367153

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

Effectiveness of Combined Tobacco Treatment in Hospitalized Subjects

Phase 4

Recruiting

Conditions: Nicotine Addiction
Nicotine Replacement Therapy
Tobacco Smoking
Tobacco Withdrawal
Nicotine Withdrawal

Interventions: Drug: Nicotine replacement therapy (Nicotine patches)
Drug: Bupropion

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-23

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 134

Registration Number: NCT06254001

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, Ciudad de mexico, Mexico

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

Phase 4

Recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: AXS-05
Drug: Bupropion

First Posted Date: 2024-01-25

Last Posted Date: 2024-05-13

Lead Sponsor: Axsome Therapeutics, Inc.

Target Recruit Count: 350

Registration Number: NCT06223880

Locations: 🇺🇸
Clinical Research Site, Everett, Washington, United States

Voxelotor CYP and Transporter Cocktail Interaction Study

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor
Drug: Bupropion
Drug: Metformin
Drug: Repaglinide
Drug: Furosemide
Drug: Rosuvastatin
Drug: Flurbiprofen
Drug: Omeprazole
Drug: Midazolam

First Posted Date: 2023-08-08

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 44

Registration Number: NCT05981365

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986419
Drug: Caffeine
Drug: Bupropion
Drug: Flurbiprofen
Drug: Omeprazole
Drug: Midazolam
Drug: Fexofenadine

First Posted Date: 2023-07-06

Last Posted Date: 2023-10-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT05932277

Locations: 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Phase 3

Recruiting

Conditions: Smoking Cessation

Interventions: Drug: Bupropion

First Posted Date: 2023-02-17

Last Posted Date: 2024-02-29

Lead Sponsor: University of Kansas Medical Center

Target Recruit Count: 500

Registration Number: NCT05732272

Locations: 🇺🇸
University of Kansas Medical Center, Kansas City, Missouri, United States

SMART Trial to Predict Anhedonia Response to Antidepressant Treatment

Phase 4

Recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: Sertraline
Drug: Bupropion

First Posted Date: 2022-09-13

Last Posted Date: 2023-10-04

Lead Sponsor: Mclean Hospital

Target Recruit Count: 183

Registration Number: NCT05537584

Locations: 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy